Jupiter Neurosciences, Inc. Announces Research Breakthrough With JOTROL™ In Parkinson’s Disease

Jupiter Neurosciences, Inc. (Jupiter)— a clinical-stage pharmaceutical company advancing a pipeline focused on the treatment of central nervous system (CNS) disorders and rare diseases—announced topline proof-of-concept preclinical data with its proprietary resveratrol drug product, JOTROL™, for Parkinson's Disease (PD). JOTROL™, Jupiter's unique and patented platform product, is an enhanced orally administered resveratrol formulation designed to safely deliver therapeutically relevant levels of resveratrol.

In collaboration with scientists Shaun Brothers, Ph.D., MBA and Candace Carriere, Ph.D. at the University of Miami School of Medicine, Jupiter recently completed preclinical activities in a validated mouse model . . .